Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
First received: June 6, 2011
Last updated: November 18, 2013
Last verified: November 2013
This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid levels.
||Observational Model: Cohort
Time Perspective: Retrospective
||A Retrospective Survey to Evaluate the Impact of Hyzaar on Uric Acid in the Management of Hypertensive Patients in Normal Practice
Primary Outcome Measures:
Secondary Outcome Measures:
- The Percentage of Patients With Hyperuricemia [ Time Frame: Baseline and Month 3 ] [ Designated as safety issue: No ]
Hyperuricemia was defined as SUA >6.6mg/dL in females and >7.7mg/dL in males.
- Diastolic Blood Pressure (DBP) [ Time Frame: Baseline and Month 3 ] [ Designated as safety issue: No ]
DBP at baseline and month 3.
- Systolic Blood Pressure (SBP) [ Time Frame: Baseline and Month 3 ] [ Designated as safety issue: No ]
SBP at baseline and month 3.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2010 (Final data collection date for primary outcome measure)
Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
|Ages Eligible for Study:
||20 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Data from 33 physicians from different levels of hospitals were invited to provide information on patients who received MK-0954A and had pre- and post-treatment serum uric acid and lipid profile reports during the study period. Each physician could provide up to 30 clinical charts of patients matching the inclusion criteria for the study.
- Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg
- Serum creatinine >2 mg/dL
No Contacts or Locations Provided
No publications provided
||Merck Sharp & Dohme Corp.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 6, 2011
|Results First Received:
||August 2, 2011
||November 18, 2013
||Taiwan: Institutional Review Board
Keywords provided by Merck Sharp & Dohme Corp.:
Essential hypertension Uric acid Retrospective Hyzaar
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 11, 2013
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs